Neuroinflammation and Alzheimer Disease: Clinical and Therapeutic Implications
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
In Alzheimer disease brains, the amyloid plaques are closely associated with a locally induced, nonimmune-mediated, chronic inflammatory response without any apparent influx of leukocytes from the blood. The present findings indicate that in cerebral A beta diseases (Alzheimer disease, Down syndrome, hereditary cerebral hemorrhage with amyloidosis-Dutch type), the clinical symptoms are determined to a great extent by the site of inflammatory response. It was found that the formation of the amyloid-microglia complex seems to be a relatively early pathogenic event that precedes the process of severe destruction of the neuropil. The idea that inflammation is implicated in Alzheimer pathology has received support from the epidemiologic studies indicating that the use of anti-inflammatory drugs can prevent or retard the Alzheimer disease process. In this contribution, we review the relationship between inflammation and clinical manifestation and the opportunities for anti-inflammatory treatments in Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“The cholinergic and noradrenergic neurotransmission is disturbed as a consequence of decreased activity of the remaining cholinergic neurons in the basal forebrain and activation of the remaining neurons in the locus coeruleus (Davies and Maloney, 1976; Salehi et al., 1994; Hoogendijk et al., 1999).”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 2×
“…led to the controversial concept that AD may be a primarily amyloid-driven process, with the neuritic tau-pathology (neurofibrillar tangles and neuropil threads) being an important secondary phenomenon that is closely correlated with the syndrome of dementia (Hardy and Allsop, 1991; Selkoe, 1991).”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 2×
“Epidemiologic studies indicating that the use of antiinflammatory drugs can prevent or retard AD have strongly stimulated the idea of treating AD patients with anti-inflammatory drugs (Breitner, 1996; McGeer et al., 1996).”
BackgroundResultActivation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314 · cited 1×
“The activated microglial cells produce and release potentially toxic products, including reactive oxygen species (Klegeris et al., 1994; Meda et al., 1995; Van Muiswinkel et al., 1996b), proinflammatory cytokines, excitotoxins (Giulian et al., 1995, 1996) and proteases, which could damage the…”
BackgroundMCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“During the past 15 years, a variety of inflammatory proteins were reported to be associated the neuritic plaques (Eikelenboom et al, 1994; McGeer and McGeer, 1995).”
BackgroundThe Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
Eikelenboom, P., & Stam, F. C. (1982) · Acta Neuropathologica · doi:10.1007/bf00685397 · Cited by 454
Self-citationBrain microglia constitutively express β-2 integrins
Akiyama, H., & McGeer, P. L. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90055-r · Cited by 430 · cited 1×
“…of activated microglia-expressing receptors for the inactivated form of complement factor C3 (CD11b/CD18 and CD11c/CD18) (Rozemuller et al., 1989a; Akiyama and McGeer, 1990), combined with the in vitro findings that the A peptide can bind and activate C1 (Rogers et al., 1992), indicates an…”
Background
Cited by
Pathogenic mechanisms following ischemic stroke
Khoshnam, S. E., Winlow, W., Farzaneh, M., Farbood, Y., & Moghaddam, H. F. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2938-1 · Cited by 621
Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases
Togo, T., Akiyama, H., Iseki, E., Kondo, H., Ikeda, K., Kato, M., Oda, T., Tsuchiya, K., & Kosaka, K. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00496-9 · Cited by 481
“, 1998), multiple sclerosis (Raine, 1997) and autoimmune encephalitis, as well as a number of disorders such as cerebrovascular diseases (Becker, 1998) and Alzheimer’s disease (AD) (McGeer and McGeer, 1995; Neuroinflammation Working Group, 2000; Akiyama, 2000; Eikelenboom et al., 2000).”
BackgroundVenkateshappa, C., Harish, G., Mahadevan, A., Srinivas Bharath, M. M., & Shankar, S. K. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0755-8 · Cited by 232
“Similar to mitochondrial damage, neuroinflammation with microglial activation and reactive gliosis are evident during AD with enhanced expression of the astroglial marker GFAP [9, 10, 31].”
BackgroundZhang, L., Li, Y., Wu, X., Hong, Z., & Wei, W. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13021 · Cited by 113
“…of proinflammatory molecules are responsible for neurotoxic processes in several neurodegenerative conditions, such as Alzheimer’s disease (AD) (Eikelenboom et al. 2000; Alvarez et al. 2007), Parkinson’s disease (Matusevicius et al. 1996; Dobbs et al. 1999), and HIV-associated dementia (Achim…”
BackgroundLoss of tau rescues inflammation-mediated neurodegeneration
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Cardona, A. E., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00196 · Cited by 91
“First, a large number of inflammatory cells (microglia and astrocytes) and molecules (cytokines, chemokines, complement components, etc...) are present at elevated levels in the AD brain (Eikelenboom et al., 2000; Akiyama et al., 2000; McGeer and McGeer, 2001).”
Background
Metadata
- Authors
- Eikelenboom, P., Rozemuller, A. J. M., Hoozemans, J. J. M., Veerhuis, R., & van Gool, W. A.
- Venue
- Alzheimer Disease and Associated Disorders
- Published
- 2000
- Volume
- 14
- Issue
- Supplement
- Pages
- S54-S61
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W2081780162
- Cited by
- 78
- References
- 19
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroinflammation and Alzheimer Disease: Clinical and Therapeutic Implications. https://app.cochat.ai/papers/10.1097/00002093-200000001-00009
- The paper
- Eikelenboom, P., Rozemuller, A. J. M., Hoozemans, J. J. M., Veerhuis, R., & van Gool, W. A. (2000). Neuroinflammation and Alzheimer Disease: Clinical and Therapeutic Implications. Alzheimer Disease and Associated Disorders. https://doi.org/10.1097/00002093-200000001-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.